Three cases of bone metastases in patients with gastrointestinal stromal tumors

Rare Tumors

Volumn 3, Issue 2, 2011, Pages 51-53

  di Scioscio, Valerio ^a   Greco, Laura ^a   Pallotti, Maria Caterina ^a   Pantaleo, Maria Abbondanza ^a   Maleddu, Alessandra ^a   Nannini, Margherita ^a   Bazzocchi, Alberto ^a   di Battista, Monica ^a   Mandrioli, Anna ^a   Lolli, Cristian ^a   Saponara, Maristella ^a   Giorgio, Garzillo ^a   Biasco, Guido ^a   Zompatori, Maurizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bone metastases; Computerezed tomografy; Gastrointestinal stromal tumors; Imatinib; Scan

Indexed keywords

CD34 ANTIGEN; IMATINIB; NILOTINIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; EXON; FEMALE; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAW OSTEONECROSIS; LIVER BIOPSY; LOW BACK PAIN; MALE; MITOSIS INDEX; TUMOR VOLUME;

EID: 79955566387     PISSN: 20363605     EISSN: 20363613     Source Type: Journal    
DOI: 10.4081/rt.2011.e17     Document Type: Article

References (22)

1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-465.
2. Miettinen M, Lasota J. Gastronitestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.
4. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastronitestinal stromal tumors. N Engl J Med 2002;347:472-480.
5. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastronitestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
7. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759.
8. Casali PG, Jost L, Reichardt P, et al. ESMO guidelines working group. Gastro -intestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20: 64-67.
9. Nannini M, Biasco G, Di Scioscio V, et al. Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors. Oncol Rep 2011;25:113-120.
10. Barrière J, Thariat J, Vandenbos F, et al. Diplopia as the first symptom of an aggressive metastatic rectal stromal tumor. Onkologie 2009;32:345-347.
11. Kaku S, Tanaka T, Ohtuka T, et al. Perisacral gastrointestinal stromal tumor with intracranial metastasis. Case report. Neurol Med Chir 2006;46:254-257.
12. Ozan E, Oztekin O, Alacacioǧlu A, et al. Esophageal gastrointestinal stromal tumor with pulmonary and bone metastases. Diagn Interv Radiol 2010;16:217-220.
13. Tezcan Y, Koc M. Gastrointestinal stromal tumor of the rectum with bone and liver metastasis: a case study. Med Oncol 2010 Oct 17. [Epub ahead of print]
14. Tariq Z, Ghose A et al. Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases. Am J Ther 2010 June 25. [Epub ahead of print]
15. Saad F. New research findings on zole-dronic acid: survival, pain, and antitumor effects. Cancer Treat Rev 2008;34:183-192.
16. Machado M, Cruz LSC, Tannus G, Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Therap 2009;31 962-979.
17. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2010; D003188.
18. Berenson JR. Therapeutic options in the management of myeloma bone disease. Semin Oncol 2010;37:S20-29.
19. Green JR. Antitumor effects of bispho-sponates. Cancer 2003 Feb; 97 suppl 3:840-847
20. Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphospho-nates. Semin Oncol 2010;37:530-540.
21. Koto K, Murata H, Kimura S, et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 2010;24:233-239.
22. Di Salvatore M, Orlandi A, Bagalà C, et al. Anti-tumour and anti-angiogenetic effects of zolederonic acid on human non small-cell lung cancer cell line. Cell Prolif 2011; 44:139-146.